Join the Adbry group to help and get support from people like you.
Adbry News
FDA Approves Adbry (tralokinumab-ldrm) Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)
MADISON, N.J.--(BUSINESS WIRE)-- June 13, 2024. LEO Pharma Inc. has today announced approval from the U.S. Food and Drug Administration (FDA) for a new Adbry (tralokinumab-ldrm) 300 mg single-dose...
LEO Pharma Inc. Announces U.S. FDA Approval of Adbry (tralokinumab-ldrm) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years
Adbry is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis specifically targeting the interleukin (IL)-13 cytokine, one of the key drivers of atopic dermatitis...
FDA Approves Adbry (tralokinumab-ldrm) for Adults with Moderate-to-Severe Atopic Dermatitis
MADISON, N.J.--(BUSINESS WIRE) December 28, 2021 --LEO Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab-ldrm) for the treatment of m...
Further information
Related condition support groups
Contact Dermatitis, Atopic Dermatitis